| Reduced rate of disease development after HIV-2 infection as compared to HIV-1 R Marlink, P Kanki, I Thior, K Travers, G Eisen, T Siby, I Traore, CC Hsieh, ... Science 265 (5178), 1587-1590, 1994 | 853 | 1994 |
| Slower heterosexual spread of HIV-2 than HIV-1 PJ Kanki, KU Travers, RG Marlink, ME Essex, S MBoup, A Gueye-NDiaye, ... The Lancet 343 (8903), 943-946, 1994 | 524 | 1994 |
| Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2 SJ Popper, AD Sarr, KU Travers, A Gueye-Ndiaye, S Mboup, ME Essex, ... The Journal of infectious diseases 180 (4), 1116-1121, 1999 | 360 | 1999 |
| Natural protection against HIV-1 infection provided by HIV-2 K Travers, S Mboup, R Marlink, A Guèye-Nidaye, T Siby, lbou Thior, ... Science 268 (5217), 1612-1615, 1995 | 255 | 1995 |
| Morbidity of infections caused by antimicrobial-resistant bacteria K Travers, B Michael Clinical Infectious Diseases 34 (Supplement_3), S131-S134, 2002 | 249 | 2002 |
| Humanistic and economic burden of generalized anxiety disorder in North America and Europe DA Revicki, K Travers, KW Wyrwich, H Svedsäter, J Locklear, MS Mattera, ... Journal of affective disorders 140 (2), 103-112, 2012 | 214 | 2012 |
| Excess infections due to antimicrobial resistance: the “Attributable Fraction” M Barza, K Travers Clinical Infectious Diseases 34 (Supplement_3), S126-S130, 2002 | 181 | 2002 |
| Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa PJ Kanki, S M'boup, D Ricard, F Barin, F Denis, C Boye, L Sangare, ... Science 236 (4803), 827-831, 1987 | 180 | 1987 |
| Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes P Kanki, S M'Boup, R Marlink, K Travers, CC Hsieh, A Gueye, C Boye, ... American journal of epidemiology 136 (7), 895-907, 1992 | 127 | 1992 |
| Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs JM Stelling, K Travers, RN Jones, PJ Turner, TF O'Brien, SB Levy Emerging Infectious Diseases 11 (6), 873, 2005 | 103 | 2005 |
| Review of assessments of the human health risk associated with the use of antimicrobial agents in agriculture JC Bailar III, K Travers Clinical infectious diseases 34 (Supplement_3), S135-S143, 2002 | 60 | 2002 |
| A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation K Weisel, C Doyen, M Dimopoulos, A Yee, JJ Lahuerta, A Martin, ... Leukemia & lymphoma 58 (1), 153-161, 2017 | 51 | 2017 |
| Clusters of lymphoma in ferrets SE Erdman, PJ Kanki, FM Moore, SA Brown, TA Kawasaki, KW Mikule, ... Cancer investigation 14 (3), 225-230, 1996 | 44 | 1996 |
| Burden and management of chronic kidney disease in Japan: systematic review of the literature K Travers, A Martin, Z Khankhel, KS Boye, LJ Lee International journal of nephrology and renovascular disease, 1-13, 2013 | 38 | 2013 |
| Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16 … UA Matulonis, L Walder, TJ Nøttrup, P Bessette, S Mahner, M Gil-Martin, ... Journal of Clinical Oncology 37 (34), 3183-3191, 2019 | 33 | 2019 |
| Protection from HIV-1 infection by HIV-2 KU Travers, GE Eisen, RG Marlink, ME Essex, CC Hsieh, S Mboup, ... Aids 12 (2), 224-225, 1998 | 32 | 1998 |
| Policy recommendations FAAIR Scientific Advisory Panel Clinical Infectious Diseases 34 (Supplement_3), S76-S77, 2002 | 28* | 2002 |
| Interaction with human immunodeficiency virus (HIV) type 2 predicts HIV type 1 genotype AD Sarr, JL Sankalé, DJ Hamel, KU Travers, A Gueye-Ndiaye, M Essex, ... Virology 268 (2), 402-410, 2000 | 28 | 2000 |
| Risk factors for HIV-1 and HIV-2 infection in pregnant women in Dakar, Senegal RC Abbott, A NDour-Sarr, A Diouf, T NDoye, D Bâ, N Tall, N MBaye, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 7 (7), 711-717, 1994 | 28 | 1994 |
| Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study JR Gallagher, KJ Heap, S Carroll, K Travers, B Harrow, SN Westin Future Oncology 15 (36), 4197-4206, 2019 | 23 | 2019 |
